Fig. 7.

Predicted outcomes for humans receiving micafungin at 400 mg/day who are infected with the various strains. (A) Humanization of micafungin in the mouse. Micafungin has been administered in silico to a mouse every 12 h to simulate the mean concentration-time profile of micafungin in the serum for humans receiving 400 mg/day. The dashed line represents the 2.5th and 97.5th centiles for the population. (B) Predicted antifungal effect of the humanized regimen for the wild type. The broken line represents the growth in untreated hosts. (C) Predicted antifungal effect of the humanized regimen for the heterozygous mutant. (D) Predicted antifungal effect of the humanized regimen for the mutant strains.